Pulmicort^® HFA-MDI

Partner: AstraZeneca

Protecting the Environment: from CFC to HFA

This new hydrofluoroalkane (‘HFA’) metered dose inhaler (“MDI”) contains AstraZeneca's inhaled corticosteroid Pulmicort® (budesonide) and was developed for territories outside of the US. It was filed for marketing authorisation for the treatment of asthma in adults and children in 2005 on a country-by-country basis in Europe and has since been approved in a number of countries.

The more environmentally friendly HFA-MDI is designed to replace the currently available MDI formulation of Pulmicort® which uses chlorofluorocarbons (CFCs) as the propellant.

SkyePharma developed this new product using its proprietary formulation technology, and also conducted the clinical development programme for AstraZeneca.

For further information on Pulmicort® HFA-MDI see AstraZeneca.

SkyePharma's hydrofluoroalkane formulation technology is available for a wide range of additional applications.

SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom

Pulmicort